secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001493152-23-016391
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharma Q1 revenue $5.3M (+144% YoY); net loss narrows to $2.7M
-------------------------------------------------------------------

- Revenue $5.3M, up 144% YoY and 52% QoQ; record sales of ALKINDI SPRINKLE and Carglumic Acid.
- Net loss $2.7M ($0.10/share) vs $5.3M loss ($0.21) in Q1 2022; cash $14.7M.
- Launched Betaine Anhydrous; acquired rare disease candidate ET-600 (NDA filing expected 2024).
- G&A expenses $5.3M (incl $0.9M non-cash) from sales force expansion; R&D $0.5M vs $1.6M.
- CEO expects profitability in near future; ninth straight quarter of sequential revenue growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000149315223016391/0001493152-23-016391-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000149315223016391/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-016391

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer